Tisdag 3 December | 21:19:08 Europe / Stockholm

Bifogade filer

Kalender

Tid*
2025-11-06 08:00 Kvartalsrapport 2025-Q3
2025-08-07 08:00 Kvartalsrapport 2025-Q2
2025-05-06 08:00 Kvartalsrapport 2025-Q1
2025-02-13 N/A Bokslutskommuniké 2024
2024-11-07 - Kvartalsrapport 2024-Q3
2024-08-08 - Kvartalsrapport 2024-Q2
2024-05-13 - X-dag ordinarie utdelning OPTOMED 0.00 EUR
2024-05-10 - Årsstämma
2024-05-07 - Kvartalsrapport 2024-Q1
2024-02-15 - Bokslutskommuniké 2023
2023-11-03 - Kvartalsrapport 2023-Q3
2023-08-04 - Kvartalsrapport 2023-Q2
2023-05-11 - X-dag ordinarie utdelning OPTOMED 0.00 EUR
2023-05-10 - Årsstämma
2023-05-05 - Kvartalsrapport 2023-Q1
2023-02-17 - Bokslutskommuniké 2022
2022-11-03 - Kvartalsrapport 2022-Q3
2022-09-06 - Extra Bolagsstämma 2022
2022-08-04 - Kvartalsrapport 2022-Q2
2022-05-11 - X-dag ordinarie utdelning OPTOMED 0.00 EUR
2022-05-10 - Årsstämma
2022-05-05 - Kvartalsrapport 2022-Q1
2022-02-17 - Bokslutskommuniké 2021
2021-11-04 - Kvartalsrapport 2021-Q3
2021-08-05 - Kvartalsrapport 2021-Q2
2021-05-06 - Kvartalsrapport 2021-Q1
2021-04-29 - X-dag ordinarie utdelning OPTOMED 0.00 EUR
2021-04-28 - Årsstämma
2021-02-18 - Bokslutskommuniké 2020
2020-11-25 - Kvartalsrapport 2020-Q3
2020-08-27 - Kvartalsrapport 2020-Q2
2020-06-12 - X-dag ordinarie utdelning OPTOMED 0.00 EUR
2020-06-11 - Årsstämma
2020-05-29 - Kvartalsrapport 2020-Q1
2020-02-28 - Bokslutskommuniké 2019

Beskrivning

LandFinland
ListaSmall Cap Helsinki
SektorHälsovård
IndustriMedicinteknik
Optomed är verksamt inom medicinteknik. Bolaget bedriver forskning och utveckling av specialiserade ögonkameror. Utveckling sker av både hård- och mjukvara som vidaresäljs under olika varumärken. Verksamhet innehas på global nivå, med störst närvaro inom den nordiska marknaden. Kunderna består av forskningsinstitut samt sjukhus. Huvudkontoret ligger i Oulu.
2024-05-17 09:30:00

Optomed PlcStock Exchange Release17 May 2024 at 10.30, Helsinki

Optomed's Board has resolved upon a new option plan

Optomed's board of directors has resolved upon a new option plan. The resolution is based on the authorization given by the general meeting of 10 May 2024.

Option plan 2024A:

The total number of options is 300,000 and each option entitled to one share of the company. The options are offered to the CEO and certain key employees. The purpose of the plan is to retain and incentifize the CEO and other key employees. The subscription price is EUR 4.62. The subscription price is based on the average closing prices of the last 30 trading days on Nasdaq Helsinki. The subscription period is 1 January 2026 - 31 December 2028.

The theoretical market value of one option under the plan 2024A is approximately EUR 2.107 per stock option and the theoretical total market value of the plan 2024A is approximately 632,100 euros in total. The theoretical market value of a stock option has been calculated by using the Black & Scholes stock option pricing model with the following input factors: share price EUR 5.65 euros, subscription price EUR 4.62 risk free interest rate 2.95%, validity of stock options approximately 3 years and volatility 55.2%.

The complete terms and conditions of the option plan 2024A are attached to this release.

Optomed Plc

Further enquiries

Petri Salonen, Chairman, Optomed Plc, petri.salonen@optomed.com

Optomed in Brief

Optomed is a Finnish medical technology company and one of the leading providers of handheld fundus cameras. Optomed combines handheld cameras with software and artificial intelligence with the aim to transform the diagnostic process of blinding eye diseases such as rapidly increasing diabetic retinopathy. In its business Optomed focuses on eye screening devices and software solutions related R&D in Finland and sales through different channels in over 60 countries.

www.optomed.com